Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
NCT04493502 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 26, 2020
- Completion date
- October 13, 2022
- Enrollment
- 72 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.